News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY), reMYND Sign $637M Early-Stage Parkinson, Alzheimer Deal


9/7/2010 8:12:48 AM

LONDON, Sept 7 (Reuters) - Roche (ROG.VX) boosted its early-stage central nervous system (CNS) drug pipeline on Tuesday by signing a drug development deal for new Parkinson's and Alzheimer's disease medicines with Belgium's reMYND.


comments powered by Disqus
Roche
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES